Project Grant R01CA305812
Award Date 9/1/25
Completion Date 8/31/30
Dollars Obligated $851K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Florida, USA
Similar Awards
- The National Cancer Institute (NCI) awarded a $168,500 Project Grant under the "Cancer Cause and Prevention Research" (CFDA 93.393) program to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. in Tampa, Florida. The two-year grant, with an ultimate completion date of July 31, 2025, aims to evaluate physical and mental health symptoms (patient-reported outcomes) throughout the cancer diagnosis trajectory and their associations with cancer outcomes among HIV-positive...
- This $2,991,283 Project Grant was awarded on September 23, 2025 by the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. in Florida. The grant will fund a two-pronged research approach to (1) leverage a large electronic health record database to characterize trends and outcomes of lung cancer screening among people with and without HIV in the U.S., and (2) partner with community clinics serving...
- The National Cancer Institute (NCI), part of the U.S. Department of Health and Human Services, awarded a $734,942 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. in Tampa, Florida. The project, titled "Aging, DNA Methylation, and Incident Cardiovascular Disease in Breast Cancer Survivors," aims to generate new blood DNA methylation data and conduct research to better...
- The National Cancer Institute (NCI), part of the U.S. Department of Health and Human Services, awarded a $1,338,648 Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to the University of Pittsburgh. The grant will fund a "Hybrid Type I Cluster Randomized Effectiveness-Implementation Trial of CARES" to address clinically significant levels of depression, pain, and fatigue experienced by over 18 million Americans living with cancer. The project aims to...
- The National Cancer Institute (NCI), under the Cancer Cause and Prevention Research program (CFDA 93.393), awarded a $825,966 Project Grant to The University of Texas MD Anderson Cancer Center to conduct a randomized controlled trial. The grant aims to test the effects of a multilevel, culturally adapted storytelling intervention to address stigma at both patient and provider levels for Zambian women living with cancer and HIV (WLC+H). The patient-level intervention will randomly assign 240...
- The National Cancer Institute (NCI) awarded a $432,304 Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to The Trustees of Columbia University in the City of New York, Health Sciences Division. The grant, awarded on January 3, 2025, supports a 5-year research project focused on "Enhanced Cancer Risk Predictions in Underrepresented Populations through Robust Multi-Source Data Integration." The project aims to develop novel data integration methods to...
- The National Cancer Institute (NCI), through the Cancer Cause and Prevention Research program (CFDA 93.393), awarded a $130,301 Project Grant to The Johns Hopkins University. The grant, awarded on September 5, 2025, will support research to extend the Surveillance, Epidemiology, and End Results (SEER)-Medicare database, a critical data linkage that enables studies on the delivery of high-quality cancer care. As the Core Manager of the Biostatistics Shared Resource at the Sidney Kimmel...
- This $549,460 federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research by the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. in Florida to study the role of the BCL11B transcription factor in regulating CD8+ T cell response and memory in tumor microenvironments. The award aims to establish the transcriptional programs and epigenomic landscape controlled by BCL11B in mouse T cells, with the goal of understanding...
- This $432,098 Project Grant awarded by the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research by the Fred Hutchinson Cancer Center (Seattle Cancer Care Alliance) to investigate HIV persistence and treatment response in Kaposi sarcoma. The research aims to identify factors contributing to differences in clinical outcomes for Kaposi sarcoma patients in Uganda, with a focus on understanding how HIV control impacts Kaposi sarcoma tumor biology and treatment response....
- This $5,041,790 cooperative agreement award from the National Cancer Institute (NCI), under the Cancer Centers Support Grants program (CFDA 93.397), will fund research projects at the University of California, San Francisco (UCSF) to improve cancer health disparities. The key products and services to be delivered include: Three translational cancer health disparities research projects focused on meningioma, prostate cancer, and breast cancer. The projects aim to evaluate the interplay of...